Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares in Athersys (NASDAQ:ATHX) jumped by 10% earlier today after the company announced that it will present data from a phase 2 trial of its MultiStem therapy at an upcoming conference in Europe.
So What: Athersys is a clinical stage biotechnology company that is using adult stem cells to develop stem cell therapies for various indications, including ischemic stroke.
The company will present data from its phase 2 MultiStem trial in ischemic stroke patients at the European Stroke Organization Conference on Sunday, April 19th, and that presentation will provide the first look at un-blinded phase 2 data evaluating MultiStem's ability to improve patient outcomes following a stroke. In previous trials, Athersys has reported that MultiStem reduces inflammation in the ischemic area and can protect, and even rescue, damaged or injured cells, including brain tissue.
Now What: Stroke is an increasingly common and costly disease with few treatment options. Over 15 million people suffer strokes globally ever year, including 2 million people in American, Europe, and Japan. In the U.S. alone, it is estimated that direct and indirect costs associated with stroke totals more than $53 billion.
Since the chances of having a stroke increase with age and roughly half of Americans have at least one of the three major risk factors for cardiovascular disease, there's a significant need for new treatments as baby boomers get older.
For that reason, investors are right to keep an eye on Athersys' phase 2 results. However, investors should also recognize that despite being around since 1995, Athersys still doesn't have any commercial products on the market and very little in the way of collaboration revenue. That makes Athersys a very risky play suited only to the most speculative of investors.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's What Might Be Pushing Up Shares of Athersys, Inc. Today
An investment bank analyst predicts off-the-hook gains from Athersys' "off-the-shelf" stem cell treatments.
3 Stocks That Have Doubled in 2016 Alone
But beware: Not all that glitters is gold.
The Biggest Biotech Catastrophes of the Week
See which companies suffered the worst clinical setbacks in the week ending May 2.